key: cord-0902851-z7pp4288
authors: Battaglini, Denise; Robba, Chiara; Ball, Lorenzo; Silva, Pedro Leme; Cruz, Fernanda Ferreira; Pelosi, Paolo; Macedo Rocco, Patricia Rieken
title: Non-invasive respiratory support and patient self-inflicted lung injury in COVID-19: a narrative review
date: 2021-06-03
journal: Br J Anaesth
DOI: 10.1016/j.bja.2021.05.024
sha: 2dd2f84d26084500c3febbdaf4b755caca813252
doc_id: 902851
cord_uid: z7pp4288

Coronavirus disease 2019 (COVID-19) pneumonia is associated with hypoxemic respiratory failure, ranging from mild to severe. Due to the worldwide shortage of intensive care unit beds, a relatively high number of patients with respiratory failure are receiving prolonged non-invasive respiratory support, even when their clinical status would have required invasive mechanical ventilation. There are few experimental and clinical data reporting that vigorous breathing effort during spontaneous ventilation can worsen lung injury and cause a phenomenon that has been termed patient self-inflicted lung injury (P-SILI). The aim of this narrative review is to provide an overview of P-SILI pathophysiology and the role of non-invasive respiratory support in COVID-19 pneumonia. Respiratory mechanics, vascular compromise, viscoelastic properties, lung inhomogeneity, work of breathing, and oesophageal pressure swings are discussed. The concept of P-SILI has been widely investigated in recent years, but controversies persist regarding its mechanisms. To minimize the risk of P-SILI, intensivists should better understand its underlying pathophysiology to optimize the type of non-invasive respiratory support provided to patients with COVID-19 pneumonia, as well as decide on the optimal timing of intubation for these patients.

Coronavirus disease 2019 (COVID-19) may present with mild to severe symptoms, the latter often associated with acute respiratory distress syndrome (ARDS), possibly complicated by multiple organ dysfunction. 1 2 Experimental and clinical evidence on non-COVID-19 acute hypoxemic respiratory failure (AHRF) and ARDS supports the existence of ventilator-induced lung injury (VILI). 3 Despite a clear rationale, comparatively few data report that vigorous spontaneous breathing efforts during non-invasive respiratory support can worsen lung injury, inducing what has been termed "patient self-inflicted lung injury" (P-SILI). 4 5 To date, no clinical study has demonstrated that a ventilatory strategy to limit the risk of P-SILI can improve patient outcomes. [6] [7] [8] During the early phase of the COVID-19 pandemic, P-SILI was highlighted as a rationale to justify early intubation over non-invasive respiratory support. 9 Although evidence has been limited, it seems that regional strain and heterogeneity do not result in P-SILI in healthy lungs, thus raising questions regarding the mechanisms underlying P-SILI in already damaged lungs, such as in COVID- 19 . It is likely that the loss of normally aerated lung volume for the same tidal volume increases global and regional strain, as well as leads to pivotal effects on diaphragm curvature and contraction. If respiratory neuromuscular function is intact, the increased respiratory drive is translated into stronger muscle contraction and more negative pleural swings, which could result in pendelluft phenomena, tidal recruitment, pulmonary oedema, and increased regional strain. 10 However, in COVID-19, P-SILI may be only part of a complex multitude of events that can contribute as determinants of failure of non-invasive respiratory support. Attention should also be paid to the degree of hypoxemia and its effects on peripheral organs, since COVID-19 is characterized by multiple organ involvement. 1 11 Thus, invasive mechanical ventilation should be considered, but bearing in mind its possible systemic complications. 8 12 Controversy remains whether the pathophysiology of COVID-19 differs from that of conventional ARDS. [13] [14] [15] [16] Therefore, the straightforward application of concepts derived from ARDS to COVID-19 pneumonia might have drawbacks. [13] [14] [15] [16] The aim of this narrative review is to provide an overview of the pathophysiology and the role of non-invasive respiratory support in COVID-19 pneumonia. Respiratory mechanics, vascular compromise, viscoelastic properties, lung inhomogeneity, work of breathing, and oesophageal pressure swings are discussed. Different approaches are described to help the intensivist minimize the risk of P-SILI.

Once severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) enters the alveolar type II epithelial cells 17 , it begins to replicate, compromising alveolar-capillary barrier integrity and infecting other cell types, ultimately resulting in multiple organ involvement. 1 

The exact pathophysiology of pulmonary involvement in COVID-19 is still under investigation, but there is evidence showing initial alveolar collapse, lung inhomogeneity, and changes in viscoelastic properties of the lungs, 13 as well as macro-and microvascular involvement, including endothelial inflammation, oedema, and extracellular matrix injury, 18 which result in an altered ventilation/perfusion ratio (V′ A /Q′) and impairment of hypoxic vasoconstriction. 19 20 Some of these pathophysiological features are shared with other lung diseases, making the differential diagnosis quite challenging. 17 21 22 In COVID-19, low arterial partial pressure of oxygen/fraction of inspired oxygen ratio (PaO 2 /FiO 2 ) is not only associated with true shunting, but with extensive areas of low V′ A /Q′, 23 which correspond to ground-glass areas on chest computed tomography (CT). Lung biopsies obtained from patients who died from COVID-19 demonstrated a distinctive vascular feature of endothelial injury, disrupted cell membranes, and widespread thrombosis with microangiopathy. 24 The V′ A /Q′ mismatch can also be promoted by a hyperactivation of the coagulation cascade, which fosters thrombotic and embolic mechanisms, leading to higher V′ A /Q′ and physiologic dead space. 25 The natural history of COVID-19 pneumonia also involved diffuse alveolar damage after secretion of proteases and reactive oxygen species, as well as formation of antibody-virus immune complexes. 26 Finally, endothelial cell damage and dysregulated angiogenesis may promote pathological fibroproliferation. 26 The fibrotic pattern seems to be preponderant in late phases of the disease. 27 Post-mortem trans-bronchial lung cryobiopsies of COVID-19 patients admitted to the intensive care unit (ICU) showed intraalveolar hyaline membranes, alveolar oedema, and proteinaceous exudate formation, as well as a proliferative profile characterized by derangement and obliteration of the alveolar structures and fibrosis. 17 21 22 These anatomic and structural alterations result in significant changes in respiratory mechanics. 27 The mechanical stretch of lung epithelia results in increased release of tissue growth factor and lung remodeling. 28 All these mechanisms might be associated with different degrees of hypoxemia, respiratory system compliance, and potential for lung recruitment. [13] [14] [15] [16] Different phenotypes of COVID-19 have been described and modelled since the beginning of the pandemic, alternately described as different presentations of COVID-19 or distinct stages of the same disease. 9 29 In this context, a milder, earlier phenotype (L or 1) includes multiple, focal ground-glass opacities and is associated with low elastance, low V′ A /Q′ ratio, and low recruitability. An intermediate phenotype (2) represents the progression of phenotype L (or 1) to H (or 3). 29 Finally, phenotype H (or 3) is more similar to a typical ARDS pattern. 9 29 Different characteristics on chest CT have been identified in survivors versus non-survivors, 30 31 and post-mortem studies reported a highly variable degree of lung damage corresponding to these distinct phenotypes. 18 Nonetheless, patients that were actually intubated and subjected to invasive mechanical ventilation typically had high respiratory system elastance, similar to that seen in conventional ARDS. 13 Despite distinct respiratory system elastance, recruitability patterns, and clinical presentations, 15 16 20 the current literature seems to agree that COVID-19 phenotypes are the extremes of a single disease entity as it progresses, characterized by distinct host responses to SARS-CoV-2 and different levels of lung damage.

Moreover, it remains difficult to determine whether the increase in lung damage is associated with the severity of COVID-19 pneumonia per se or the type of non-invasive respiratory support strategy, which may result in P-SILI.

Therefore, an individualized approach to the management of respiratory support in COVID-19 pneumonia is required. [32] [33] [34] Mechanisms of P-SILI COVID-19 patients can present with dyspnoea and hypoxemia, which may require noninvasive or invasive respiratory support. Due to the shortage of ICU beds during the pandemic, 35 a relatively high number of patients were treated with non-invasive respiratory support for many days even when their clinical status would have required intubation and invasive mechanical ventilation, which may have led to P-SILI. In COVID-19, four potential mechanisms of P-SILI may be suggested: 1) increased lung stress/strain, 36-39 2) inhomogeneous distribution of ventilation, 4 40 3) changes in lung perfusion, 16 23 and 4) patient-ventilator asynchronies during non-invasive positive pressure ventilation (NPPV). 41 42 

Stress is defined as the distribution of forces applied per unit of lung area, represented by the transpulmonary pressure (P L ), 36 i.e. the difference between alveolar pressure and pleural pressure, estimated by oesophageal pressure (Poes), whereas strain is defined as the change in volume divided by the initial lung volume (functional residual capacity). 36 Lung stress depends on the difference between airway and pleural pressures, while strain assesses overstretch and is directly proportional to stress. 27 43 The calculation of strain is difficult at bedside, making lung stress the best surrogate of strain. 36 During spontaneous breathing, airway pressure is reduced when compared to invasive mechanical ventilation, but this does not reduce the risk of high transpulmonary pressures. In fact, P L is the distending pressure of the lung and during spontaneous breathing reflects the inspiratory effort. 5 37 Under normal spontaneous breathing conditions, during the inspiratory phase, pleural pressure is uniformly decreased, while P L is uniformly increased. 37 Importantly, at a given lung elastance, swings in P L are similar whether generated by spontaneous breathing or controlled mechanical ventilation. 5 37 Under pathological conditions, greater inspiratory efforts are needed to obtain a similar tidal volume, and early spontaneous breathing effort yields higher negative pleural pressure and P L in the dependent and more caudal regions of the lung, 37 44 45 resulting in inhomogeneous distribution of pressures and volume across the vertical gradient. When positive airway pressure is added to spontaneous breathing, as occurs during continuous positive airway pressure (CPAP) and NPPV, the resulting P L is higher, depending on positive pressure and negative oesophageal pressure swings. 10 37 39 46 In COVID-19 patients, increased efforts have been associated with higher inspiratory pressures and volumes, as well as increased P L , which may progress to barotrauma (pneumothorax and pneumomediastinum). 47 48 Recent studies emphasized that expiratory efforts may also cause P-SILI. 10 46 During excessive expiratory muscle activity, the pleural pressure increases, leading to markedly reduced P L, and collapse of most dependent lung regions, as well as of peripheral airways. 49 Thus, both high inspiratory and expiratory efforts may promote P-SILI, especially in lung diseases which feature inhomogeneous distribution, such as COVID-19.

Inspiratory pendelluft has been defined as intraparenchymal gas redistribution when the inspiratory effort has not yet induced an inspiratory flow at the airway opening. It is caused by different regional time constants or dynamic pleural pressure variations in spontaneously breathing patients, yielding significant tidal recruitment and regional overdistension of dependent regions, independent of inspired tidal volume (V T ). 50 Experimental studies suggest that pendelluft may further worsen lung damage. 4 5 50 However, limited evidence is available from the clinical setting. 50 51 A recent observational study of non-COVID-19 patients reported pendelluft in 40% of those ventilated with pressure support. 50 Upon reduction of pressure support, gases were redistributed from the ventral to the dorsal regions, doubling the baseline pendelluft volume and increasing the carbon dioxide concentration at the lowest pressure support. The higher the pendelluft volume, the higher the respiratory distress and work of breathing, increasing the risk of P-SILI.

In COVID-19 pneumonia, there are perfusion inhomogeneities (areas hyper and hypoperfused). 52 53 During spontaneous breathing with increased inspiratory effort, pulmonary capillary vessels may be compressed, thus increasing the pulmonary resistance. The increase in transalveolar and transcapillary pressures recruits previously collapsed capillary vessels as well as overdistends those located in healthy and ground-glass areas, which may lead to increased blood flow in damaged regions and alveolar-capillary membrane injury (Figure 1 ). At end-inspiration, the right atrium pressure may decrease to a lower level (below 0.27 kPa), not allowing a compensatory increase in the cardiac output (Frank-Starling law). In normal physiologic conditions, a net balance between fluids from pulmonary capillaries and the interstitium occurs, with a negative interstitial pressure which becomes more negative at increased inspiratory stress. [54] [55] [56] [57] Higher negative interstitial pressure yields greater transcapillary and transalveolar pressure gradient, facilitating injury of lung endothelial and epithelial cells as well as increased capillary perfusion and blood volume, thus leading to lung damage and oedema. [58] [59] [60] Furthermore, the pressure measured in the oesophagus underestimates interstitial pressure of around 0.78-0.98 kPa at lower stress and 1.47-1.67 kPa at higher stress. 55 Thus, during spontaneous breathing and non-invasive respiratory support, the interstitial pressure becomes progressively more negative at higher inspiratory stress, and lower at lower inspiratory stress. 54 In COVID-19, the presence of microthrombi with abnormal pulmonary circulation alters V′ A /Q′ distribution; this is compounded by hyperperfusion of poorly ventilated lung regions, which is likely the cause of hypoxemia, and by hypoperfusion of normally and poorly aerated lung regions, leading to higher V′ A /Q′ and dead spacing. 23 Noninvasive ventilatory support increases intrathoracic pressure, reduces venous return and end-diastolic volume both in the right and left cardiac cavities, improves cardiac contractility, as well as decreases both transalveolar and transcapillary pressure, thus resulting in less pulmonary damage. 61 

Patient-ventilator asynchronies are associated with worse outcomes in mechanically ventilated patients. 41 42 The most common asynchronies are ineffective effort and double triggering, which can be seen during NPPV. 41 Under-assistance carries a risk of excessive load on the respiratory muscles while increasing the tidal volume. 5 62 Stronger inspiratory efforts increase the P L , transvascular pressure gradient and tidal recruitment, with pendelluft and regional overdistension, possibly worsening injury of dependent lung regions. 5 41 Over-assistance is more difficult to detect, but may result in excessive inspiratory flow (exceeding the patient's demand), thus resulting in ineffective effort, delayed or prolonged cycling, and reverse triggering. 41 However, the threshold at which the combination of asynchronies and increased P L may lead to P-SILI is not clearly defined.

In recent years, the concept of P-SILI in spontaneously breathing patients has evolved, engendering many efforts for detection of the underlying mechanisms and development of therapeutic strategies to minimize P-SILI. Non-invasive respiratory support strategies may fail due to a variety of reasons, including P-SILI itself, high work of breathing, inadequate sedation, decreased level of consciousness, deterioration of gas exchange, interface intolerance, or underlying conditions. 63 A recent consensus of 39 experts 64 concerning the management of COVID-19-related acute respiratory failure using a Delphi method suggested that high-flow nasal oxygen therapy (HFNOT) should be used in patients who are unable to maintain peripheral oxygen saturation (SpO 2 ) > 90% despite oxygen delivery through a Venturi mask, to avoid the need for tracheal intubation and invasive mechanical ventilation. NPPV (with positive end-expiratory pressure, PEEP) should be considered when the patient's work of breathing increases progressively or in case of mixed (hypoxic and hypercapnic) respiratory failure. In case of altered mental status or hemodynamic instability, or failure of non-invasive respiratory support to maintain SpO 2 >90%, tracheal intubation should be considered, with a lung protective ventilation strategy: V T of 4-6 ml kg -1 of predicted body weight (PBW), plateau pressure (Pplat) ≤ 2.94 kPa, driving pressure ≤ 1.47 kPa, and individualized PEEP. Recruitment manoeuvres should be adopted in selected cases, while prone positioning can be safely and widely adopted. Following these recommendations, three approaches have been suggested to minimize P-SILI: 1) the limitation of tidal volume; J o u r n a l P r e -p r o o f 2) the application of PEEP; and 3) the reduction of spontaneous effort. All three of these strategies should be combined with appropriate sedation and metabolic control.

High tidal volume during non-invasive respiratory support has been associated with potential risk of lung damage and worse prognosis in non-COVID-19 patients. 65 Therefore, V T should be limited during spontaneous breathing, although this is very difficult to monitor at the bedside, especially when using HFNOT or CPAP via helmet interfaces. 65 66 

In non-COVID-19 patients, the efficacy of PEEP in reducing P-SILI is explained by less atelectatic areas and peripheral airway collapse, more homogeneous distribution of inspiratory stress, reduced regional overdistension in dependent regions, and decreased pressures generated by spontaneous efforts. 67 In a recent small RCT, PEEP did not affect pendelluft despite decreased ventilation heterogeneity. 68 That is in contrast with a previous study where PEEP reduced the amplitude of pendelluft. 69 Higher PEEP levels increase endexpiratory lung volume, acting also on the curvature of the diaphragm, possibly leading to less pulmonary and muscular injury. 70 PEEP frequently improves gas-exchange, which can potentially reduce respiratory drive. 70 Given the existence of different degrees of lung damage in COVID-19 patients, those with lower elastance of the respiratory system and poor recruitability may present alveolar overdistension and increased P L, driving pressure, and plateau pressure with high PEEP levels. 71 72 In contrast, using low PEEP levels, Pplat and P L remain within safe range, while driving pressure decreases. In severe COVID-19 patients with increased respiratory system elastance (patchy-like ARDS) higher PEEP levels may be required. 9 The common approach of applying high levels of PEEP may worsen the underlying microvascular injury 25 Figure 2 summarizes the effects on the lung during spontaneous breathing at zero-PEEP (ZEEP) and CPAP, with the addition of pressure support in a representative COVID-19 patient.

Spontaneous breathing during AHRF and ARDS is not always encouraged 73 because of the possible inhomogeneous distribution of pressures and regional volumes, which cannot be monitored with standard methods. Thus, patients at risk of P-SILI should be promptly recognized and managed through a two-pronged strategy: 1) adequate sedation, preferably assessed by a validated instrument such as the Richmond Agitation Sedation Scale (RASS), to minimize respiratory drive; and 2) appropriate use of neuromuscular blocking agents (NMBAs). COVID-19 pneumonia may present with a rapid onset of respiratory failure with initially preserved respiratory system elastance, reversible with few days of positivepressure ventilation, and a slow moderate-to-severe form of ARDS, which may require longer duration of mechanical ventilation and rescue therapies such as NMBAs. 33 An observational study 74 concluded that longer use of NMBA may protect patients with COVID-J o u r n a l P r e -p r o o f 19 ARDS from barotrauma. NMBAs decrease chest wall elastance, reduce patient-ventilator asynchronies, and improve lung recruitment and inflammation. 75 However, as mentioned above, COVID-19 may present at different stages of illness, which calls into question the propriety of using a one-size-fits-all strategy for all patients. Thus, more conservative approaches should be recommended, 76 but patients cannot be kept on passive mechanical ventilation for a long time, and other approaches need to be pursued. Figure 3 shows the differences in airway pressure, transpulmonary pressure, and oesophageal pressure of possible active, passive, and active plus support strategies in a representative COVID-19 patient.

In most cases, non-invasive respiratory supports represent the first steps in the complex management of COVID-19 pneumonia. 77 Gattinoni and colleagues claimed that early intubation and mechanical ventilation should be prioritized in severe COVID-19 pneumonia in order to prevent progression to more severe lung injury. 33 However, this assertion was not based on strong scientific evidence 78 79 and should be interpreted cautiously. Spontaneous breathing is known to be beneficial in mild to moderate cases of ARDS (non-COVID-19). 80 81 Indeed, recent evidence raised concern on the need for early intubation of COVID-19 patients because neither the time from ICU admission to intubation nor the use of high-flow oxygen support were associated with increased survival in COVID-19 patients. 82 Additionally, in a cohort of 4,643 COVID-19 patients, those who received NPPV or invasive mechanical ventilation on ICU admission had a higher severity of ARDS and higher 90-day mortality. 83 A recent meta-analysis in a cohort of 8,944 COVID-19 patients reported no differences on all-cause mortality between patients who undergo early versus late intubation. 78 Moreover, early intubation may be unavailable in some locations or unnecessary (if patient severity is low, the patient is well adapted to non-invasive respiratory support despite hypoxemia, or because of clinical misjudgement). 82 84 Large-scale provision of respiratory support is the main problem of COVID-19 pandemic, since the number of available ICU beds is often lower than the number of patients requiring assistance. 85 Non-invasive respiratory support, when possible, requires lower doses of sedatives, causes less delirium, facilitates mobilization, and prevents secondary infections and ICU-acquired weakness. 86 Interestingly, when compared with non-COVID-19 patients, COVID patients receiving non-invasive respiratory support were burdened by a 2-fold higher risk of failure. 87 The following paragraphs discuss the main non-invasive respiratory supports used in COVID-19 pneumonia: 1) Conventional oxygen therapy (COT); 2) High-flow oxygen nasal therapy (HFONT); 3) CPAP; and 3) NPPV.

Non-intubated COVID-19 patients who receive various levels of oxygen support are still susceptible to sudden increases in P L with possible lung damage, favouring the development of pneumothorax or pneumomediastinum. [87] [88] [89] COT is a readily available, low-complexity, first-line respiratory support modality, which requires less monitoring and specialized staff. However, it may not be considered for patients with increased inspiratory effort. 88 90 High-flow nasal oxygen therapy Early in the COVID-19 pandemic, international scientific societies suggested that HFNOT should be avoided because of the potential risk of airborne exposure to SARS-CoV-2 when compared to COT. 91-93 However, the rationale for this recommendation came from weak evidence. The correct use of face masks and other personal protective equipment (PPE) reduces exposure to droplets and aerosol among front-line healthcare workers 94 enough to making these strategies a viable first-step therapy before NPPV and invasive mechanical ventilation is considered. More recent guidelines suggested HFNOT as first-line oxygen therapy as long as staff are wearing adequate PPE. 93 The WHO 95 recommended strict monitoring (for 1 hour) of patients at high risk of intubation by experienced personnel in case of respiratory deterioration. HFNOT, compared with COT, has not been associated with increased survival, even though it reduced the rate of invasive mechanical ventilation and ventilator free days. 96 97 COVID-19 patients who present reduced PaO 2 /FiO 2 are at higher risk of NIV failure, 98 and the availability of devices which can provide HFNOT may be limited during this global health crisis. HFNOT may create a low level of PEEP, but it is unable to prevent P-SILI. 81 Additionally, the use of HFNOT during prone positioning did not result in further improvement. 99 Compared to CPAP, it has been associated with varying and controversial impacts on mortality (69% vs 36% 100 and 16% vs 30% 86 ). When compared to NPPV, HFNOT resulted in no significant difference in days free of respiratory support within 28 days. 101 In COVID-19 pneumonia patients with poorly recruitable lungs, oxygenation improvement with HFNOT may be associated with a higher and more stable inspired oxygen fraction. 102 HFNOT is promising in patients with low severity, 98 102 but not in those who need more aggressive treatments, which may increase the risk of P-SILI.

Different interfaces have been proposed to deliver CPAP to COVID-19 pneumonia patients. In a retrospective COVID-19 cohort, the use of face-mask CPAP resulted in improvement in one-third of patients, while half were ultimately intubated. 103 CPAP has been associated with lower risk of death if applied within 7 days from hospital admission. 104 In a small retrospective study, CPAP administered through a face-mask interface, compared to COT, avoided intubation from day 7 to 14. 105 In Europe, helmet CPAP has been considered the first choice for respiratory failure to minimize aerosol generation, 106 although the importance of this concern is controversial, as noted above. Both facemask and helmet CPAP have been employed in COVID-19 patients to improve oxygenation. However, CPAP J o u r n a l P r e -p r o o f failure was frequently observed, and associated with the severity of pneumonia on admission and higher inflammation. 107 Helmet CPAP treatment presents a success rate greater than 60% 108 and has been considered as a rescue therapy to improve survival. 109 One RCT is ongoing to evaluate the impact of helmet CPAP in COVID-19 pneumonia patients. 110 Non-invasive positive pressure ventilation Compared with HFNOT, helmet NPPV did not reduce the number of days free of respiratory support within 28 days but did reduce the rate of intubation. 101 Large randomized controlled trials are required to better evaluate the advantages of using helmet NPPV in COVID-19 pneumonia patients.

The recognition of patients at risk for non-invasive respiratory support failure and endotracheal intubation is of particular relevance in COVID-19. 8 Non-invasive or invasive respiratory supports may temporarily improve clinical status and oxygenation without changing the natural course of the disease. 84 101 This makes rapid recognition of patients who are at higher risk of disease progression-and, thus, of the optimal timing for intubation-quite challenging; 84 however, the literature seems to agree that patients who are at high risk of non-invasive respiratory support failure should be promptly identified and endotracheally intubated. 78 Several scores have been proposed for AHRF, but none has been validated yet in COVID-19. A useful method to apply at bedside for identifying AHRF patients at risk of non-invasive support failure is the HACOR score, 111 currently under investigation in the specific setting of COVID-19. 112 This score includes heart rate, pHa, Glasgow Coma Scale (GCS), PaO 2 /FiO 2 , and respiratory rate, and should be calculated after 1 hour of non-invasive support. In case of a HACOR score >5, intubation and MV should be provided (specificity 90% and sensitivity 72%). 113 Other scores have been proposed in the specific setting of COVID-19 (e.g., the "COVID-19 score" which includes evaluation of consciousness, oxygenation, vital capacity, ionotropic support, and lung damage on plain chest radiograph or CT scan), 114 but again, none has been validated. In one study, lung ultrasound was able to detect COVID-19 patients who would benefit from tracheal intubation. 115 Another score to predict failure of non-invasive respiratory strategies has been developed 116 and externally validated. The score includes age, number of comorbidities, respiratory rate-oxygenation index (ROX), GCS, and use of vasopressors on the first day of non-invasive respiratory support as independent predictors of failure. A retrospective observational study suggested chest radiograph findings as possible predictors of intubation. The "CORS" (COVID-19 Opacification Rating Score) was developed by assigning one point to each of the 12 lung zones of interest in which an opacity was observed. This score was predictive of intubation at <24 hours, <48 hours, and during admission (all, p<0.001). 117 The Pneumonia Severity Score has also been recognized as an independent predictor of intubation in COVID-19 (p<0.001). 118 Higher V T alone is also a good predictor of need for intubation and non-invasive support failure. However, it is very hard to control and monitoring V T during non-invasive support, and the main driver of larger V T is the respiratory drive. 46 119 As theorized two decades ago, the higher the dead space and minute ventilation, the greater the severity of ARDS. 120 The use of heated and humidified oxygen at high flow rates, as in HFNOT, can reduce the dead space and yield survival benefits. 46 119 For patients treated with HFNOT, a ROX index (SpO 2 /FiO 2 /respiratory rate) <2.85, <3.47, and <3.85 indicates need for intubation after 2, 6, and 12 hours respectively. 121 A single multicentre observational study identified the SOFA score and the ROX index as predictive tools for respiratory failure and endotracheal intubation during HFNOT in COVID-19. 122 Moreover, in the early stage, when elastance is relatively preserved, respiratory rate is not particularly high, but tidal volumes could be. 123 Consequently, transpulmonary pressure and changes in pleural pressure are preponderant, with possible haemodynamic consequences. 123 This phase may not be captured by ROX and HACOR scores, since the chemical and metabolic stimuli are the main inputs to the respiratory centres affecting the inspiratory drive. The inspiratory drive is controlled by arterial partial pressure of carbon dioxide and PaO 2 feedback loops, which are substantially modulated by sedation and metabolic alkalosis at respiratory centres. 123 If these are not properly managed, the respiratory centres may demand a relatively high minute ventilation, such as in the common scenario of hypoxemia and metabolic acidosis, leading to increased work of breathing and dyspnoea. 123 Although P L is difficult to quantify during non-invasive ventilation, several strategies have proven promising. The energy expended by the diaphragm correlates well with work of breathing and can be easily derived by subtracting oesophageal pressure (Poes) from the gastric pressure. Changes in Poes can correlate well with inspiratory effort, while work of breathing is well represented by the Poes pressure-time product, which, to be realistic, should rely on variations in chest-wall pressure. Although promising, these methods need validation and may involve some manoeuvres which are difficult to perform in spontaneously breathing patients (airway occlusion and measurement of V T ). 63 Apigo and colleagues recently proposed a new score for evaluating work of breathing at the bedside in COVID-19. This scale includes respiratory rate, nasal flaring on inspiration, sternocleidomastoid use, and abdominal muscle use for a maximum of 7 points; intubation is proposed if the total score exceeds 4. 124 Figure 4 shows a possible strategy to recognize patients at risk of non-invasive respiratory support failure. The degree of lung impairment and patients' comorbidities remain key factors to understand which device and respiratory support could be more suitable for each patient to avoid intubation and mechanical ventilation and prevent P-SILI. 114 117 The complexity of COVID-19, including different pulmonary features (such as organizing fibrosis), endothelial injury, thromboembolism, neurological, kidney and myocardial injuries, has made management of this disease even more complex than first expected. 2 125 J o u r n a l P r e -p r o o f CONCLUSIONS The concept of P-SILI has been widely investigated in recent years, even though controversies persist regarding its mechanisms. To minimize the risk of P-SILI, intensivists should better understand the pathophysiology of this condition to optimize the modality of non-invasive respiratory support provided to COVID-19 patients, as well as determine the optimal timing of intubation for those in whom non-invasive support fails. Interstitial pressure is normally higher than pleural pressure, and higher when stress is greater. This suggest that transpulmonary pressure measured by oesophageal pressure (Poes) may underestimate actual transalveolar and transcapillary pressure and its potential injurious effects on the lung. Panels A, B, C, D represent different interstitial and capillary pressures after changes of extravascular pressure and their effects. Representative example of spontaneous breathing in patients with severe COVID-19. During spontaneous breathing at ZEEP or CPAP, the airway pressure (P AW ) is zero (at zero PEEP, ZEEP) or equal to PEEP (if CPAP) in the non-dependent regions of the lung, while it is equal to the superimposed pressure plus PEEP (CPAP) or ZEEP in the dependent (more ventilated) regions. The transpulmonary pressure (P TP ) is higher in dependent lung regions and increases as the oesophageal pressure becomes more negative (Poes) (Part a, b) . Conversely, in dependent lung areas, when a positive support pressure is applied to mechanically ventilated lungs (even if the patient is breathing spontaneously), the resulting P AW will be equal to the selected support plus PEEP, while the Poes and P TP will be lower than during spontaneous breathing (Part c). In non-dependent regions, when a support pressure is applied to mechanically ventilated but spontaneously breathing lungs, the P AW will be equal to the sum of PEEP, pressure support (Ps), and superimposed pressure, with a lower value of PTP and Poes with regard to spontaneously breathing, non-ventilated patients (Part d). CPAP, continuous positive pressure ventilation; PEEP, positive endexpiratory pressure; MV, mechanical ventilation; ZEEP, zero PEEP. Legend: CPAP, continuous positive airway pressure; PEEP, positive end-expiratory pressure; ZEEP, zero PEEP; P TP , transpulmonary pressure; Poes, oesophageal pressure.; P AW , airway pressure. 

Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2

Multiorgan and Renal Tropism of SARS-CoV-2

Ventilator-Induced Lung Injury

The Comparison of Spontaneous Breathing and Muscle Paralysis in Two Different Severities of Experimental Lung Injury*

Spontaneous breathing during lung-protective ventilation in an experimental acute lung injury model

Clinical management of severe acute respiratory infection when novel coronavirus ( 019-nCoV) infection is suspected: interim guidance

COVID-19: scientific reasoning, pragmatism and emotional bias

Caution about early intubation and mechanical ventilation in COVID-19

COVID-19 pneumonia: different respiratory treatments for different phenotypes?

A physiological approach to understand the role of respiratory effort in the progression of lung injury in SARS-CoV-2 infection

Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions

Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study

Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study

Respiratory physiology of COVID-19-induced to ARDS of other etiologies

Computed tomography assessment of PEEP-induced alveolar recruitment in patients with severe COVID-19 pneumonia

Physiological and quantitative CT-scan characterization of COVID-19 and typical ARDS: a matched cohort study

Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study

Dual-Energy Computed Tomography of the Lung in COVID-19 Patients: Mismatch of Perfusion Defects and Pulmonary Opacities

Potential for Lung Recruitment and Ventilation-Perfusion Mismatch in Patients With the Acute Respiratory Distress Syndrome From Coronavirus Disease

Fibrotic progression and radiologic correlation in matched lung samples from COVID-19 post-mortems

Acute Interstitial Pneumonia (AIP): Relationship to Hamman-Rich Syndrome, Diffuse Alveolar Damage (DAD), and Acute Respiratory Distress Syndrome (ARDS)

The impact of ventilation-perfusion inequality in COVID-19: a computational model

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Management of COVID-19 Respiratory Distress

COVID-19 pulmonary pathology: a multiinstitutional autopsy cohort from Italy and New York City

Ventilatory support and mechanical properties of the fibrotic lung acting as a "squishy ball

Mechanical stress induces lung fibrosis J o u r n a l P r e -p r o o f by epithelial-mesenchymal transition*

Distinct phenotypes require distinct respiratory management strategies in severe COVID-19

Different computed tomography patterns of Coronavirus Disease 2019 (COVID-19) between survivors and non-survivors

A Pattern Categorization of CT Findings to Predict Outcome of COVID-19 Pneumonia

Emerging therapies for COVID-19 pneumonia

COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome

Ten things you need to know about intensive care unit management of mechanically ventilated patients with COVID-19

A Closer Look Into Global Hospital Beds Capacity and Resource Shortages During the COVID-19 Pandemic

Understanding Pulmonary Stress-Strain Relationships in Severe ARDS and Its Implications for Designing a Safer Approach to Setting the Ventilator

Do spontaneous and mechanical breathing have similar effects on average transpulmonary and alveolar pressure? A clinical crossover study

Protecting lungs during spontaneous breathing: what can we do?

ECMO criteria for influenza A (H1N1)-associated ARDS: role of transpulmonary pressure

Static and Dynamic Transpulmonary Driving Pressures Affect Lung and Diaphragm Injury during Pressure-controlled versus Pressure-support Ventilation in Experimental Mild Lung Injury in Rats

Patient-ventilator asynchronies during mechanical ventilation: current knowledge and research priorities

Asynchronies during mechanical ventilation are associated with mortality

Static and Dynamic Contributors to Ventilatorinduced Lung Injury in Clinical Practice. Pressure, Energy, and Power

Esophageal Manometry and Regional Transpulmonary Pressure in Lung Injury

Spontaneous Effort During Mechanical Ventilation

Transpulmonary pressure: importance and limits

COVID-19 and pneumothorax: a multicentre retrospective case series

Pulmonary Barotrauma in Mechanical Ventilation

Expiratory Resistances Prevent Expiratory Diaphragm Contraction, Flow Limitation, and Lung Collapse

Occurrence of pendelluft under pressure support ventilation in patients who failed a spontaneous breathing trial: an observational study

Inspiratory Efforts, Positive End-Expiratory Pressure, and External Resistances Influence Intraparenchymal Gas Redistribution in Mechanically Ventilated Injured Lungs

Dual-Energy CT Pulmonary Angiography (DECTPA) Quantifies Vasculopathy in Severe COVID-19 Pneumonia

In vivo demonstration of pulmonary microvascular involvement in COVID-19 using dual-energy computed tomography

Interstitial pressure and lung oedema in chronic hypoxia

Parenchymal stress affects interstitial and pleural J o u r n a l P r e -p r o o f pressures in in situ lung

Lymphatic Vessels and Their Surroundings: How Local Physical Factors Affect Lymph Flow

Transmural pressure in rat initial subpleural lymphatics during spontaneous or mechanical ventilation

Adverse Heart-Lung Interactions in Ventilator-induced Lung Injury

Understanding negative pressure pulmonary edema

Pleural Mechanics and Fluid Exchange

Clinical review: Positive end-expiratory pressure and cardiac output

The tidal volume fix and more…

Patient self-inflicted lung injury: implications for acute hypoxemic respiratory failure and ARDS patients on noninvasive support

Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method

Failure of Noninvasive Ventilation for De Novo Acute Hypoxemic Respiratory Failure

Tidal Volume Estimation during Helmet Noninvasive Ventilation: an Experimental Feasibility Study

Regional distribution of transpulmonary pressure

Effects of inspiratory flow on lung stress, pendelluft, and ventilation heterogeneity in ARDS: a physiological study

Qualitative and quantitative assessment of pendelluft: a simple method based on electrical impedance tomography

Patient self-inflicted lung injury and J o u r n a l P r e -p r o o f positive end-expiratory pressure for safe spontaneous breathing

The 'baby lung' became an adult

Lung Stress and Strain in Acute Respiratory Distress Syndrome

Respiratory drive in the acute respiratory distress syndrome: pathophysiology, monitoring, and therapeutic interventions

Neuromuscular blocking agents (NMBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study

The Use of Neuromuscular Blocking Agents in the ICU

Sedation, Analgesia, and Paralysis in COVID-19 Patients in the Setting of Drug Shortages

Noninvasive ventilation for COVID-19-associated acute hypoxaemic respiratory failure: experience from a single centre

Effect of timing of intubation on clinical outcomes of critically ill patients with COVID-19: a systematic review and meta-analysis of non-randomized cohort studies

Ventilatory Mechanics in Early vs Late Intubation in a Cohort of Coronavirus Disease

Long-Term Effects of Spontaneous Breathing During Ventilatory Support in Patients with Acute Lung Injury

Spontaneous breathing affects the spatial ventilation and perfusion distribution during mechanical ventilatory support*

Timing of Intubation and Mortality Among Critically Ill Coronavirus Disease 2019 Patients: A Single-Center Cohort Study

COVID-ICU group for the R network and the C-I investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study

Use of non-invasive ventilation for patients with COVID-19: a cause for concern?

The "helmet bundle" in COVID-19 patients undergoing non invasive ventilation

Feasibility and clinical impact of out-of-ICU noninvasive respiratory support in patients with COVID-19-related pneumonia

High Failure Rate of Noninvasive Oxygenation Strategies in Critically Ill Subjects With Acute Hypoxemic Respiratory Failure Due to COVID-19

Spontaneous subcutaneous emphysema and pneumomediastinum in non-intubated patients with COVID-19

Predictors of Pneumothorax/Pneumomediastinum in Mechanically Ventilated COVID-19 Patients

Comparison of high-flow nasal oxygen therapy with conventional oxygen therapy and noninvasive ventilation in adult patients with acute hypoxemic respiratory failure: A meta-analysis and systematic review

Faculty of Intensive Care Medicine, Intensive Care Society A of A and RC of A. Critical care preparation and management in the COVID-19 pandemic

Recomendaciones de consenso respecto al soporte respiratorio no invasivo en el paciente adulto con insuficiencia respiratoria aguda secundaria a infección por SARS-CoV-2

Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)

Risk of COVID-19 among front-line healthcare workers and the general community: a prospective cohort study

High flow nasal oxygen therapy to avoid invasive mechanical ventilation in SARS-CoV-2 pneumonia: a retrospective study

High-Flow Nasal Cannula in Critically III Patients with Severe COVID-19

The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing

Awake prone positioning does not reduce the risk of intubation in COVID-19 treated with high-flow nasal oxygen therapy: a multicenter, adjusted cohort study

Successful awake proning is associated with improved clinical outcomes in patients with COVID-19: single-centre high-dependency unit experience

Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure

Non-invasive CPAP in mild and moderate ARDS secondary to SARS-CoV-2

Continuous Positive Airway Pressure (CPAP) facemask ventilation is an easy and cheap option to manage a massive influx of patients presenting acute respiratory failure during the SARS-CoV-2 outbreak: A retrospective cohort study. den Uil C, editor

CPAP management of COVID-19 respiratory failure: a first quantitative analysis from an inpatient service evaluation

Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: a two-period retrospective case-control study

Helmet CPAP to Treat Acute Hypoxemic Respiratory Failure in Patients with COVID-19: A Management Strategy Proposal

Helmet CPAP treatment in patients with COVID-19 pneumonia: a multicentre cohort study

Noninvasive Ventilatory Support of COVID-19 Patients Outside the Intensive Care Units (WARd-COVID)

Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak

Helmet continuous positive airway pressure versus high-flow nasal cannula in COVID-19: a pragmatic randomised clinical trial (COVID HELMET)

Validity of a clinical scale in predicting the failure of non-invasive ventilation in hypoxemic patients

NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure

Early prediction of noninvasive ventilation failure in COPD patients: derivation, internal validation, and external validation of a simple risk score

COVID-19 Score" can predict the need for tracheal intubation in critically ill COVID-19 patients -A hypothesis

Lung ultrasound score predicts outcomes in COVID-19 patients admitted to the emergency department

A simple nomogram for predicting failure of non-invasive respiratory strategies in adults with COVID-19: a retrospective multicentre study

Chest radiograph at admission predicts early intubation among inpatient COVID-19 patients

The prognostic value of pneumonia severity score and pectoralis muscle Area on chest CT in adult COVID-19 patients

High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure

Pulmonary Dead-Space Fraction as a Risk Factor for Death in the Acute Respiratory Distress Syndrome

An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High-Flow Therapy

Predictors of failure with high-flow nasal oxygen therapy in COVID-19 patients with acute respiratory failure: a multicenter observational study

Respiratory Drive in Critically Ill Patients. Pathophysiology and Clinical Implications

Development of a work of breathing scale and monitoring need of intubation in COVID-19 pneumonia

Neurological Manifestations of Severe SARS-CoV-2 Infection: Potential Mechanisms and Implications of Individualized Mechanical Ventilation Settings

Identification and first-line management of non-invasive respiratory support failure

One of the most sensitive and specific scores for the detection of non-invasive respiratory support failure in acute hypoxemic respiratory failure is the HACOR (sensitivity 72%, specificity 90% 1 hour after initiation)

Coma Scale; PaO 2 /FiO 2 , partial pressure of oxygen/fraction of inspired oxygen; EPAP, end-expiratory airway pressure; Poes

ROX, rate oxygenation index; SpO 2 , peripheral oxygen saturation; CPAP, continuous positive airway pressure, HFNOT, high flow nasal oxygen therapy; NPPV, non-invasive positive pressure ventilation

We express our gratitude to Mrs. Moira Elizabeth Schottler and Mr. Filippe Vasconcellos for their assistance in editing the manuscript.

The authors declare that they have no conflicts of interest.